Global Efficacy Study of MPC-7869 to Treat Patients With Alzheimer's
NCT00322036
·
clinicaltrials.gov ↗
PHASE3
Phase
TERMINATED
Status
800
Enrollment
INDUSTRY
Sponsor class
Stopped
Myriad has discontinued the development of Flurizan.
Conditions
Alzheimer Disease
Dementia
Interventions
DRUG:
MPC-7869
DRUG:
MPC-7869
Sponsor
Myrexis Inc.